Leishmaniasis is a parasitic infectious disease caused by
Leishmania spp. (
1). About 70,000 deaths are caused by leishmaniasis every year across the world. Besides, 350 million people are at risk of CL, and around 1.5 - 2 million new cases are reported in the globe annually (
2). According to the WHO report, leishmaniasis is one of the six main diseases in tropical regions (
3).
Leishmaniasis occurs in three main clinical forms: mucocutaneous leishmaniasis (MCL), visceral leishmaniosis (VL), and cutaneous leishmaniasis (CL) that is the most prevalent type (
4). Cutaneous leishmaniasis is a vector-borne skin infection that is still one of the important health problems in the world, especially in tropical and subtropical countries (
2,
5,
6). Its incidence is increasing worldwide, and it is considered as one of the most important neglected diseases (
2). Cutaneous leishmaniasis causes skin lesions such as papules, nodules, or plaques with a period of six to 12 months (
7). Although the disease is self-limited, it leaves scars on the skin, causing mental and psychological complications for the patients (
8). Cutaneous leishmaniasis is caused mainly by
Leishmania major and
Leishmania tropica, which are causative agents for zoonotic cutaneous leishmaniosis (ZCL) and anthroponotic cutaneous leishmaniosis (ACL), respectively (
9). Over 90% of CL cases occur in seven countries, including Brazil, Saudi Arabia, Algeria, Afghanistan, Syria, Peru, and Iran (
10-
14).
Iran is one of the most common endemic diseases for CL. The prevalence of the disease has been reported from 1.8 to 37.9 in different parts of Iran, and 56,546 CL patients were identified in this country from 2011 to 2013 (
5,
15). Mashhad is the second-most populous city in Iran and one of the important endemic areas of CL in the country (
16-
18).